Evidence map›Paper›PMID 20685001›Full record

ArticleHealth policy (Amsterdam, Netherlands)2011

Are breast cancer navigation programs cost-effective? Evidence from the Chicago Cancer Navigation Project.

Talar W Markossian, Elizabeth A Calhoun

Abstract read
In one paragraph

Article in Health policy (Amsterdam, Netherlands), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Patient Navigation in Breast Cancer Treatment and Survivorship: A Systematic Review.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
    Article
  7. Article
  8. Review
  9. Article
  10. Impact of patient navigation on cancer diagnostic resolution among Northwest Tribal communities.Journal of cancer education : the official journal of the American Association for Cancer Education · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Talar W MarkossianHealth Policy and Management, Georgia Southern University, Jiann-Ping Hsu College of Public Health, P.O. Box 8015, Statesboro, GA 30460-8015, United States. tmarkossian@georgiasouthern.edu
Elizabeth A Calhoun
Georgia Southern University · USUniversity of Illinois Chicago · US

Funding

Chicago Cancer Navigation ProjectU01CA116875 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROSEN, STEVEN TERRY · 2005 to 2011
$4.5M
NCI NIH HHS 1 U01 CA 116875-01NCI NIH HHS U01 CA116875
6 · The paper itself

Abstract

objectivesOne of the aims of the Chicago Cancer Navigation Project (CCNP) is to reduce the interval of time between abnormal breast cancer screening and definitive diagnosis in patients who are navigated as compared to usual care. In this article, we investigate the extent to which total costs of breast cancer navigation can be offset by survival benefits and savings in lifetime breast cancer-attributable costs.

methodsData sources for the cost-effectiveness analysis include data from published literature, secondary data from the NCI's Surveillance Epidemiology and End Results (SEER) program, and primary data from the CCNP.

resultsIf women enrolled in CCNP receive breast cancer diagnosis earlier by 6 months as compared to usual care, then navigation is borderline cost-effective for $95,625 per life-year saved. Results from sensitivity analyses suggest that the cost-effectiveness of navigation is sensitive to: the interval of time between screening and diagnosis, percent increase in number of women who receive cancer diagnosis and treatment, women's age, and the positive predictive value of a mammogram.

conclusionsIn planning cost-effective navigation programs, special considerations should be made regarding the characteristics of the disease, program participants, and the initial screening test that determines program eligibility.

Indexed as

AdultAgedBreast NeoplasmsChicagoCost-Benefit AnalysisDelivery of Health CareEfficiency, OrganizationalFemaleHealth Services AccessibilityHumansMass ScreeningMiddle AgedProgram EvaluationSEER ProgramTime Factors

Identifiers

PMID20685001
PMCPMC3005996
OpenAlexW2043732749

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.